The US FDA Approves FoundationOne CDx for Alunbrig (brigatinib) in Patients with ALK+ NSCLC
Shots:
- The US FDA has approved FoundationOne CDx to be used as a CDx for Alunbrig (brigatinib) which is approved for the treatment of adult patients with ALK+ mNSCLC as detected by an FDA-approved test
- In Sept’20- Foundation Medicine and Takeda collaborated to develop CDx for therapies in its late-stage lung portfolio
- FoundationOne CDx is the only FDA-approved tissue-based CGP test and is now able to detect ALK+ mNSCLC and identify patients who may be appropriate for treatment with Alunbrig which is approved as a 1L or later-line therapy
| Ref: Business Wire | Image: WRAL TechWire
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com